EVM
DNLI icon

Eaton Vance Management’s Denali Therapeutics DNLI Stock Holding History

Eaton Vance Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23,057
Closed -$742K – 1638
2022
Q1 		$742K Buy
+23,057
New +$793K ﹤0.01% 1429

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Eaton Vance Management's DNLI Position: Q2 2022 in Review

Eaton Vance Management sold out of Denali Therapeutics (DNLI) in Q2 2022, closing a stake of 23,057 shares — an estimated $742K sold.

Eaton Vance Management first reported a position in DNLI in Q1 2022 and held it in 1 quarter. The position peaked at $742K in Q1 2022. 188 funds tracked by Wall St. Rank hold DNLI as of Q2 2022.

  • Eaton Vance Management reported no remaining Denali Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Eaton Vance Management sold 23,057 Denali Therapeutics shares in Q2 2022, an estimated $742K.
  • Eaton Vance Management first reported a position in Denali Therapeutics in Q1 2022 and held it in 1 quarter.
  • Eaton Vance Management's Denali Therapeutics position peaked at $742K in Q1 2022.
  • 188 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.